GaryD

Alnylam and RNAi: The Truth Hurts

Buffoontycoon thinks that monoclonal antibodies are a fad. Let's see here...www.pharmaweek.com/Exc...

He must be more buffoon than tycoon!

In all seriousness, it takes a long time to get all the details of a new drug technology worked out. Monoclonal antibody technology was invented in the 1970s but drugs based on these technologies took another 20 to 30 years to come to market. Now, they are hugely important and profitable.

Alnylam has a long road ahead of it and admittedly it might fail, but it has an unbelievable scientific and business team behind it, is very well funded, and has collaborations from here to China. They have completed a Phase II study of their lead drug for respiratory syncytial virus infection of the lungs (ALN-RSV01: clinicaltrials.gov/ct2...) and have initiated a second one (see clinicaltrials.gov/ct2...).

To see the kind of hurdles that Alnylam must clear, you can read this article: www.rnainews.com/issue...

RNAi is a very exciting and promising technology. I own ALNY and hope very much that they are able to commercialize this incredibly promising technology. Humanity will be better off if Alnylam is successful.